Wegovy Pill-FDA-Approved for Weight Loss

Wegovy Pill: A New Era in Weight Loss Medication

In late 2025, the U.S. Food and Drug Administration (FDA) approved the first and only oral GLP‑1 receptor agonist specifically for weight management: the Wegovy® pill (oral semaglutide). This marks a major milestone in obesity treatment and expands options for patients who prefer a daily tablet over weekly injections.

💊 What Is the Wegovy Pill?

Wegovy® is an oral formulation of semaglutide, the same active ingredient that has powered injectable GLP‑1 therapies like the original Wegovy and Ozempic. Unlike weekly injections, the pill is taken once daily, making it a much more convenient option for many patients.

The pill was approved based on data from phase 3 trials showing meaningful weight loss — on par with its injectable counterpart.

📉 How Effective Is It?

The pivotal OASIS 4 clinical trial demonstrated impressive weight loss results:

• ≈16–17% average body weight reduction in adults with obesity or overweight when taken daily alongside diet and exercise.

• Over one‑third of participants lost 20% or more of their body weight.

• Compared to placebo, which saw minimal change (~2–3%), the difference underscores the drug’s clinical impact.

These results are similar to those seen with the weekly injectable version of Wegovy, which has become a cornerstone of obesity care.

📆 When Is It Available?

The FDA approval of the pill came in December 2025, with broad availability in the U.S. beginning January 2026. It’s now stocked in tens of thousands of pharmacies and offered through providers and telehealth services.

Early rollout data suggests strong patient interest and widespread prescription uptake soon after launch.